Bionano Genomics (NASDAQ:BNGO) Upgraded at Wall Street Zen

Bionano Genomics (NASDAQ:BNGO) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also recently commented on the company. Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. HC Wainwright reduced their target price on Bionano Genomics from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.00.

Bionano Genomics Trading Down 2.5%

Bionano Genomics stock opened at $1.16 on Friday. The stock has a market cap of $13.32 million, a P/E ratio of -0.27 and a beta of 1.65. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.59 and a current ratio of 1.84. Bionano Genomics has a fifty-two week low of $1.06 and a fifty-two week high of $5.50. The firm’s fifty day moving average price is $1.22 and its 200-day moving average price is $1.33.

Bionano Genomics (NASDAQ:BNGO) last released its earnings results on Wednesday, May 13th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.12. The business had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $6.57 million. Bionano Genomics had a negative return on equity of 71.38% and a negative net margin of 109.94%. Equities research analysts forecast that Bionano Genomics will post -2.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BNGO. Jane Street Group LLC bought a new position in Bionano Genomics in the fourth quarter valued at $34,000. Renaissance Technologies LLC boosted its position in Bionano Genomics by 31.6% during the first quarter. Renaissance Technologies LLC now owns 48,700 shares of the company’s stock valued at $57,000 after buying an additional 11,700 shares during the period. Carret Asset Management LLC boosted its position in Bionano Genomics by 76.4% during the fourth quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after buying an additional 19,100 shares during the period. Geode Capital Management LLC boosted its position in Bionano Genomics by 148.8% during the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after buying an additional 39,928 shares during the period. Finally, DRW Securities LLC purchased a new stake in Bionano Genomics during the fourth quarter valued at about $258,000. Institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.